Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yuan Xiao Zhu, K. Martin Kortuem & A. Keith Stewart. (2013) Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leukemia & Lymphoma 54:4, pages 683-687.
Read now
Read now
Frederick A Luzzio & William D Figg. (2004) Thalidomide analogues: derivatives of an orphan drug with diverse biological activity. Expert Opinion on Therapeutic Patents 14:2, pages 215-229.
Read now
Read now
Frank A Wollheim. (2002) TNF inhibition as therapy for rheumatoid arthritis. Expert Opinion on Investigational Drugs 11:7, pages 947-953.
Read now
Read now
Articles from other publishers (40)
Bin Wang, Wanting Qiang, Jia Yi, Shouhong Gao, Bosu Meng, Yuhui Mu, Bolong Wang, Zhipeng Wang & Xia Tao. (2023) Simultaneous quantification of thalidomide, lenalidomide and pomadomide in plasma by LC-MS/MS. Journal of Pharmacological and Toxicological Methods 120, pages 107250.
Crossref
Crossref
Santhamani Ramasamy & Selvakumar Subbian. 2023. Handbook of Animal Models in Neurological Disorders. Handbook of Animal Models in Neurological Disorders
343
352
.
Maliha Khan, Fredrick Hagemeister, Michael Wang & Sairah Ahmed. (2022) A review of pathobiology and therapies for classic Hodgkin lymphoma. Blood Reviews 55, pages 100949.
Crossref
Crossref
Isaac Park, Tra Mi Phan & Jing Fang. (2021) Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q. Cancers 13:20, pages 5084.
Crossref
Crossref
Tiffany Li, David Mizrahi, David Goldstein, Matthew C. Kiernan & Susanna B. Park. (2021) Chemotherapy and peripheral neuropathy. Neurological Sciences 42:10, pages 4109-4121.
Crossref
Crossref
Sara Ovejero & Jerome Moreaux. (2021) Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma. Exploration of Targeted Anti-tumor Therapy.
Crossref
Crossref
Selvakumar Subbian & Gilla Kaplan. 2021. Advances in Host-Directed Therapies Against Tuberculosis. Advances in Host-Directed Therapies Against Tuberculosis
275
282
.
Alli Murugesan, Grégoire Lassalle-Claux, Lauren Hogan, Elise Vaillancourt, Ayyoub Selka, Katie Luiker, Min Ji Kim, Mohamed Touaibia & Tony Reiman. (2020) Antimyeloma Potential of Caffeic Acid Phenethyl Ester and Its Analogues through Sp1 Mediated Downregulation of IKZF1-IRF4-MYC Axis. Journal of Natural Products 83:12, pages 3526-3535.
Crossref
Crossref
Ranjeet Kumar, Afsal Kolloli, Pooja Singh, Christopher Vinnard, Gilla Kaplan & Selvakumar Subbian. (2020) Thalidomide and Phosphodiesterase 4 Inhibitors as Host Directed Therapeutics for Tuberculous Meningitis: Insights From the Rabbit Model. Frontiers in Cellular and Infection Microbiology 9.
Crossref
Crossref
Jing Ma, Qian Li, Zhen Yu, Zeng Cao, Su Liu, Lin Chen, Han Li, Shuang Gao, Tinghui Yan, Yafei Wang & Qiang Liu. (2017) Immunotherapy Strategies Against Multiple Myeloma. Technology in Cancer Research & Treatment 16:6, pages 717-726.
Crossref
Crossref
A.V. Petrov, D.V. Motorin, O.S. Pokrovskaya, E.S. Urnova, M.V. Nareiko, D.V. Babenetskaya, Yu.A. Alekseeva, L.L. Girshova, L.P. Mendeleeva & A.Yu. Zaritskii. (2017) Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of "Double Refractory". Clinical oncohematology 10:3, pages 372-380.
Crossref
Crossref
Howard Safran, Kevin P. Charpentier, Andreas Kaubisch, Kalyan Mantripragada, Gregory Dubel, Kimberly Perez, Katherine Faricy-Anderson, Thomas Miner, Yoko Eng, Joel Victor, Angela Plette, Joseph Espat, Pamela Bakalarski, Patti Wingate, David Berz, Denise Luppe, Diane Martel, Kayla Rosati & Santiago Aparo. (2015) Lenalidomide for Second-line Treatment of Advanced Hepatocellular Cancer. American Journal of Clinical Oncology 38:1, pages 1-4.
Crossref
Crossref
Ahmed Omran, Muhammad Usman Ashhab, Na Gan, Huimin Kong, Jing Peng & Fei Yin. (2013)
Effects of MRP8, LPS, and Lenalidomide on the Expressions of TNF-
α
, Brain-Enriched, and Inflammation-Related MicroRNAs in the Primary Astrocyte Culture
. The Scientific World Journal 2013, pages 1-9.
Crossref
Crossref
Selvakumar Subbian, Liana Tsenova, Paul O'Brien, Guibin Yang, Mi-Sun Koo, Blas Peixoto, Dorothy Fallows, Veronique Dartois, George Muller & Gilla Kaplan. (2011) Phosphodiesterase-4 Inhibition Alters Gene Expression and Improves Isoniazid ? Mediated Clearance of Mycobacterium tuberculosis in Rabbit Lungs. PLoS Pathogens 7:9, pages e1002262.
Crossref
Crossref
Ming Jen Tsai, Chinpiao Chen, Sung-Ho Chen, Yen Ta Huang & Ted H. Chiu. (2011) Pomalidomide suppresses cerulein-induced acute pancreatitis in mice. Journal of Gastroenterology 46:6, pages 822-833.
Crossref
Crossref
Irina Idler, Nupur Bhattacharya, Hartmut D?hner, Stephan Stilgenbauer & Daniel Mertens. (2011) Immune modulatory agents in hematopoietic malignancies. Cancer Treatment Reviews 37, pages S2-S7.
Crossref
Crossref
Claudia Pessoa, Paulo Michel P. Ferreira, Letícia Veras C. Lotufo, Manoel O. de Moraes, Suellen M. T. Cavalcanti, Lucas Cunha D. Coêlho, Marcelo Z. Hernandes, Ana Cristina L. Leite, Carlos A. De Simone, Vlaudia M. A. Costa & Valdênia M. O. Souza. (2010) Discovery of Phthalimides as Immunomodulatory and Antitumor Drug Prototypes. ChemMedChem 5:4, pages 523-528.
Crossref
Crossref
Boris Böll, Peter Borchmann, Max S. Topp, Mathias Hänel, Katrin S. Reiners, Andreas Engert & Ralph Naumann. (2010) Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. British Journal of Haematology 148:3, pages 480-482.
Crossref
Crossref
Scott G. Stewart, Carlos J. Braun, Marta E. Polomska, Mahdad Karimi, Lawrence J. Abraham & Keith A. Stubbs. (2010) Efforts toward elucidating Thalidomide’s molecular target: an expedient synthesis of the first Thalidomide biotin analogue. Organic & Biomolecular Chemistry 8:18, pages 4059.
Crossref
Crossref
Alessandra Ferrajoli, Bang-Ning Lee, Ellen J. Schlette, Susan M. O'Brien, Hui Gao, Sijin Wen, William G. Wierda, Zeev Estrov, Stefan Faderl, Evan N. Cohen, Changping Li, James M. Reuben & Michael J. Keating. (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:11, pages 5291-5297.
Crossref
Crossref
Asher A. Chanan-Khan & Bruce D. Cheson. (2008) Lenalidomide for the Treatment of B-Cell Malignancies. Journal of Clinical Oncology 26:9, pages 1544-1552.
Crossref
Crossref
Cindy H. Chau, William Dahut & William D. Figg. 2008. Angiogenesis. Angiogenesis
387
394
.
Naomi Galili, Jan Cerny & Azra Raza. (2007) Current Treatment Options: Impact of Cytogenetics on the Course of Myelodysplasia. Current Treatment Options in Oncology 8:2, pages 117-128.
Crossref
Crossref
Dominique Verhelle, Laura G. Corral, Kevin Wong, Jessica H. Mueller, Laure Moutouh-de Parseval, Kristen Jensen-Pergakes, Peter H. Schafer, Roger Chen, Emilia Glezer, Gregory D. Ferguson, Antonia Lopez-Girona, George W. Muller, Helen A. Brady & Kyle W.H. Chan. (2007) Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells. Cancer Research 67:2, pages 746-755.
Crossref
Crossref
Frederick A. Luzzio, Damien Y. Duveau & William D. Figg. (2006) A Chiral Pool Approach toward the Synthesis of Thalidomide Metabolites. HETEROCYCLES 70:1, pages 321.
Crossref
Crossref
John Gerecitano & Owen A. O’Connor. 2006. Hodgkin’s and Non-Hodgkin’s Lymphoma. Hodgkin’s and Non-Hodgkin’s Lymphoma
413
460
.
V. Lima, G. A. C. Brito, F. Q. Cunha, C. G. Reboucas, B. A. A. Falcao, R. F. Augusto, M. L. P. Souza, B. T. Leitao & R. A. Ribeiro. (2005) Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. European Journal of Oral Sciences 113:3, pages 210-217.
Crossref
Crossref
S.A. Schey, P. Fields, J.B. Bartlett, I.A. Clarke, G. Ashan, R.D. Knight, M. Streetly & A.G. Dalgleish. (2004) Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology 22:16, pages 3269-3276.
Crossref
Crossref
J. Blake Bartlett, Keith Dredge & Angus G. Dalgleish. (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nature Reviews Cancer 4:4, pages 314-322.
Crossref
Crossref
J B Bartlett, A Michael, I A Clarke, K Dredge, S Nicholson, H Kristeleit, A Polychronis, H Pandha, G W Muller, D I Stirling, J Zeldis & A G Dalgleish. (2004) Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. British Journal of Cancer 90:5, pages 955-961.
Crossref
Crossref
James M O'Donnell & Han-Ting Zhang. (2004) Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends in Pharmacological Sciences 25:3, pages 158-163.
Crossref
Crossref
Maria R Nasca, Giuseppe Micali, Nina H Cheigh, Lee E West & Dennis P West. (2003) Dermatologic and Nondermatologic Uses of Thalidomide. Annals of Pharmacotherapy 37:9, pages 1307-1320.
Crossref
Crossref
Peter H. Schafer, Anita K. Gandhi, Michelle A. Loveland, Roger S. Chen, Hon-Wah Man, Paul P. M. Schnetkamp, Gregor Wolbring, Sowmya Govinda, Laura G. Corral, Faribourz Payvandi, George W. Muller & David I. Stirling. (2003) Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immunomodulatory Drugs. Journal of Pharmacology and Experimental Therapeutics 305:3, pages 1222-1232.
Crossref
Crossref
Seema Singhal & Jayesh Mehta. (2003) Novel Therapies in Multiple Myeloma. International Journal of Hematology 77:3, pages 226-231.
Crossref
Crossref
Noopur Raje & Kenneth C. Anderson. (2002) Thalidomide and immunomodulatory drugs as cancer therapy. Current Opinion in Oncology 14:6, pages 635-640.
Crossref
Crossref
K Dredge, J B Marriott, C D Macdonald, H-W Man, R Chen, G W Muller, D Stirling & A G Dalgleish. (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. British Journal of Cancer 87:10, pages 1166-1172.
Crossref
Crossref
Andrea Thiele, Renate Bang, Michael G?tschow, Manuela Rossol, Sebastian Loos, Kurt Eger, Gisa Tiegs & Sunna Hauschildt. (2002) Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide. European Journal of Pharmacology 453:2-3, pages 325-334.
Crossref
Crossref
Tracy E. Kim & John R. Murren. (2012) Angiogenesis in Non-Small Cell Lung Cancer. American Journal of Respiratory Medicine 1:5, pages 325-338.
Crossref
Crossref
J B MARRIOTT, I A CLARKE, K DREDGE, G MULLER, D STIRLING & A G DALGLEISH. (2002)
Thalidomide and its analogues have distinct and opposing effects on TNF-
α
and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells
. Clinical and Experimental Immunology 130:1, pages 75-84.
Crossref
Crossref
Keith Dredge, J. Blake Marriott, Stephen M. Todryk, George W. Muller, Roger Chen, David I. Stirling & Angus G. Dalgleish. (2002) Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity. The Journal of Immunology 168:10, pages 4914-4919.
Crossref
Crossref